Join AcelRx Pharmaceuticals (Nasdaq: ACRX) for a KOL panel discussion on the anticoagulant market for dialysis and the Niyad NEPHRO CRRT Study.   If approved, Niyad would be the first FDA-approved regional anticoagulant for  patients undergoing continuous renal replacement therapy (CRRT).  The panel discussion will be led by Dr. Pamela Palmer, co-founder of AcelRx and feature Laurence W. Busse MD, MBA (Emory University School of Medicine) and David W. Boldt, MD (UCLA Health).

 Discussion Agenda

• Market Opportunity:  There are over 3 million acute kidney injury (AKI) patients and 37 million chronic kidney disease patients in the United States.  Over 500,000 AKI patients annually undergo dialysis and another 525,000 end-stage renal disease patients undergo outpatient dialysis annually.  Niyad has a projected peak sales of over $200M/year.
• Product Candidate Profile:  Niyad has a differentiated product profile within the existing treatment landscape.
• Upcoming Registrational Study: AcelRx will conduct its registrational study to evaluate Niyad beginning in Q4 2023.  Niyad has received Breakthrough Device Designation Status from the FDA and is currently being evaluated under an Investigational Device Exemption (IDE).
• Value driving catalysts: AcelRx is expecting its first patient enrolled in the fourth quarter of 2023 and anticipates receiving topline data in mid-2024 with a PMA submission expected in the second half of 2024.

A live question and answer session will follow the formal presentations.